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Tumors are tissue-speciﬁc diseases, and their mecha-
nisms of invasion and metastasis are highly diverse. In
breast cancer, biomarkers that speciﬁcally correlate with
the invasive phenotypes have not been clearly identi-
ﬁed. A small GTPase Arf6 primarily regulates recycling
of plasma membrane components. We have shown that
Arf6 and its effector AMAP1 (DDEF1, DEF1, ASAP1 and
centaurin β4) are abnormally overexpressed in some
breast cancers and used for their invasion and metas-
tasis. Overexpression of these proteins is independent
of the transcriptional upregulation of their genes, and
occurs only in highly malignant breast cancer cells. We
recently identiﬁed GEP100 (BRAG2) to be responsible
for the Arf6 activation to induce invasion and metas-
tasis, by directly binding to ligand-activated epidermal
growth factor receptor (EGFR). A series of our stud-
ies revealed that for activation of the invasion pathway
of EGFR, it is prerequisite that Arf6 and AMAP1 both
are highly overexpressed, and that EGFR is activated
by ligands. Pathological analyses indicate that a sig-
niﬁcant large population of human ductal cancers may
utilize the EGFR-GEP100-Arf6-AMAP1 pathway for their
malignancy. Microenvironments have been highly impli-
cated in the malignancy of mammary tumors. Our results
reveal an aspect of the precise molecular mechanisms of
some breast cancers, in which full invasiveness is not
acquired just by intracellular alterations of cancer cells,
but extracellular factors from microenvironments may
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also be necessary. Possible translation of our knowledge
to cancer therapeutics will also be discussed.
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Development of tumor malignancy, including the acqui-
sition of abnormal invasive and metastatic activities, is a
consequence of the accumulation of genetic mutations in
tumor cells. However, in the case of mammary tumors,
biomarkers that speciﬁcally correlate with their invasive
phenotypes have not been clearly identiﬁed, in spite of
extensive research including those on genomic mutations
and gene expression (1–4). Accordingly, the molecular
machineries speciﬁcally involved in the invasion of breast
tumorcellshavenotbeenclearlyunderstood.Ontheother
hand, Liu et al. (5) have recently proposed a 186-gene
‘invasiveness’ gene signature. This signature, however,
appears to rather represent a signature of oncogenic
transformation, and may not directly mediate invasion (6).
The Arf family of small GTPases regulate membrane
trafﬁcking and remodeling (7). Arf GTPases are conserved
throughout eukaryotic evolution (http://smart.embl-
heidelberg.de/smart/do_annotation.pl?DOMAIN=ARF&
BLAST=DUMMY&EVOLUTION=Show#Evolution). Inter-
estingly, Arf GTPases are found in early eukaryotes such
as Giardia lamblia, in which no members of the Ras family
of GTPases are found (8). This fact implies that control
of membrane trafﬁc and remodeling by Arf GTPases is
more essential for some eukaryotic life than the control
of proliferation and life cycle by Ras GTPases. There
are six isoforms of Arf GTPases in mammals (Arf1-6),
although Arf2 has been lost in humans. Arfs are classiﬁed
into three classes by structural similarity: class I (Arf1-3),
class II (Arf4 and 5) and class III (Arf6). Class I and class
II Arfs primarily function at the Golgi, and are involved
in intracellular secretory processes (9). On the other
hand, Arf6 is the most divergent of the Arf isoforms,
and primarily functions at cell peripheries by regulating
endocytosis and recycling-back of plasma membrane
components, as well as several types of cell surface
receptors (10). Several functions of Arf6 are closely linked
to the functions of Rac, and Arf6 has been shown to play
pivotal roles also in actin-cytoskeletal remodeling at the
cell periphery (10–12). Arf6 has moreover been shown
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Figure 1: Schematic representation of
proteins discussed in this review.
to play crucial roles in higher orders of various cellular
functions (13–15), including Fcγ-receptor-mediated
phagocytosis (16), disassembly of E-cadherin-mediated
epithelial cell–cell adhesions (17,18), recycling of integrin
β1 (19), and in tumor invasion and metastasis (20,21).
Arf6 is ubiquitously expressed in different tissues and
organs in adults. We found that Arf6 and its effector
AMAP1 are abnormally overexpressed in malignant breast
cancer cells, and this Arf6 signaling pathway is speciﬁcally
involved in the invasive and metastatic activities of some
breast cancer cells. Pathological analyses also revealed
thatseveralcomponentsofthisArf6pathwayareexcellent
indicators of the invasive and malignant phenotypes of
primary breast cancers. In this article, we discuss Arf6
signaling in cancer invasion and metastasis, together
with the molecular mechanisms by which this Arf6
pathwayfunctions(Figure 1).Wealsodiscussthepossible
translation of our knowledge to cancer therapeutics.
Arf6 is Abnormally Overexpressed Only in
Highly Invasive Breast Cancer Cells
Invasive characters are diverse even among the different
cell lines of breast tumors (22,23). On the other hand,
a direct correlation between in vivo invasive phenotypes
and in vitro invasion activities has been demonstrated in
a number of different breast cancer cell lines (24,25). We
have shown that the Arf6 protein is overexpressed in all of
the highly invasive breast cancer cell lines we examined,
to levels 10- to 20-fold higher than those observed in
noninvasive breast cancer cell lines as well as human
normal mammary epithelial cells (HMECs) (20). We also
found that Arf6 is predominantly localized to invadopodia
and plays an essential role in invadopodia formation
as well as other invasion activities of different breast
cancer cells, including MDA-MB-231 (20). Our results
suggested that Arf6 might be a predictive biomarker for
the invasive phenotypes of primary cancers of the human
breast. However, in spite of our extensive efforts, we
have not succeeded in generating an anti-Arf6 antibody,
which is applicable for immunohistochemistry of clinical
specimens. Besides breast cancer, Arf6 has also been
shown to be a component of invadopodia of a melanoma
cell line LOX, although it has not been investigated as to
whether Arf6 is overexpressed in melanomas (21).
Posttranscriptional Upregulation of Arf6
Protein Expression
Gene expression proﬁling analyses have not identiﬁed
the Arf6 gene as being overexpressed in invasive ductal
carcinomas (IDCs). Our analysis on cultured breast cancer
cell lines has instead revealed that all of the breast cancer
cell lines we examined express comparable levels of Arf6
mRNA, regardless of their invasiveness (20). HMECs
also expressed high levels of Arf6 mRNA, as observed
in highly invasive breast cancer cell lines. Thus, the
selective overexpression of the Arf6 protein in highly
invasive breast cancer cells appears to be independent of
the enhanced transcription of the Arf6 gene, but may be
because of its posttranscriptional regulation. Consistent
with this notion, the 5’-untranslated region of the Arf6
mRNA is very long and possesses a very complicated
secondary structure with a very high level of free-energy
change [http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?
view=graph&val=NT_026437.11&_gene=ARF6] (Figure 2).
mTOR is one of the central kinases regulating 5’-cap-
dependent translational control (26), and is frequently
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Figure 2: The secondary structure of the 5’-untranslated regions of Arf6 mRNA and AMAP1 mRNA.
overexpressed in breast tumors (27). We however have
preliminary results indicating that Arf6 mRNA is not under
the control of mTOR (OBI, Osaka).
Suppressive Control of the Arf6 Activity by
Non-Canonical Ubiquitination, and its
Dysfunction in Breast Cancer Cells
Several small GTPases, such as H-Ras, RhoA and Rac1,
have been shown to undergo ubiquitination (28–30). Arf6
is also ubiquitinated (31). In the database there is a
protein named Fbx8, which contains a Sec7 (ArfGEF)
domain and an F-box domain (32). Members of F-box
proteins act as subunits of the Skp-Cullin-F-box (SCF)
complexes of ubiquitin E3 ligases, and primarily determine
substrate speciﬁcity of the ubiquitination through their
direct interaction with substrates (33). Fbx8 was found
to form a complex with Cullin1 through its binding
to Skp1, and mediate the ubiquitination of Arf6, but
not other Arf isoforms (31). This ubiquitination of Arf6
occurs predominantly in the polymer form, which is
however not linked to the immediate proteasomal
degradation. It has been shown that RhoA and Rac1 are
polyubiquitinated, which is linked to their proteasomal
degradation, while ubiquitination of H-Ras occurs in
mono- or di-ubiquitination forms and is not linked to the
proteasomal degradation (28–30). We have shown that
the ubiquitination of Arf6 interferes with its interaction
with guanine nucleotide exchange factors (GEFs) and
GAPs, and hence inhibits Arf6 from functioning (31).
Therefore, Fbx8-mediated ubiquitination provides a novel
suppressive mechanism of the Arf6 activity, not known
with other small GTPases. Moreover, protein expression
of Fbx8 is impaired in many breast cancer cell lines,
while its forced expression inhibits invasive activities (31).
Therefore, impaired expression of Fbx8 appears to be one
of the factors contributing to the invasive phenotypes of
some breast cancers.
AMAP1 is an Effector for GTP-Arf6 in Invasion
and Metastasis
Active forms of the Ras superfamily of small GTPases
generally interact with other proteins, called effectors,
to transmit their downstream signals. AMAP1 (also called
DDEF1 in human, DEF1 in bovine, and ASAP1 or centaurin
β4 in mouse) has an ArfGAP domain and was originally
reported to exhibit efﬁcient GTPase-activating protein
(GAP) activities against Arf1 and Arf5, but very weak
GAP activity against Arf6 (34,35). On the other hand, we
have provided several lines of evidence that AMAP1 acts
as an effector for Arf6 in tumor invasion, in addition to
its function as a GAP for other Arf isoforms. Cellular Arf6
recruits AMAP1 to sites of its activation (both the plasma
membrane and the cytoplasmic large vesicles), when
activated such as by epidermal growth factor (EGF) (36).
AMAP1 co-localizes with Arf6 at invadopodia, and its
knockdown effectively blocks invadopodia formation and
invasive activities (37).
Biochemically, AMAP1, via its ArfGAP domain, binds
directly and stably to GTP-Arf6 without immediate
hydrolysis even in the presence of divalent cations, while
this domain exhibits only marginal levels of the stable
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binding to GDP-Arf6 nor to Arf1 and Arf5, regardless of
their nucleotide binding status (36). All of these properties
a r ea l s os h a r e dw i t hA M A P 2 / P A G 3 / P a p α close isoform
of AMAP1 (38). We have already discussed why ArfGAPs
like AMAP1 and AMAP2 should have such complicated
properties, exhibiting enzymatic GAP activities to theclass
I and II Arfs on one hand and binding to the class III Arf
(i.e. Arf6) on the other (14,39).
AMAP1 is an Indicator of the Malignant
Potentials of Breast Cancer
Like Arf6, AMAP1 is also abnormally overexpressed
(>10 fold) in highly invasive breast cancer cell lines, as
compared with weakly- and noninvasive breast cancer
cell lines and HMECs (37). Immunohistochemical analysis
also revealed that AMAP1 protein expression is very high
in all of the IDCs, n = 19, while its expression is at basal
levels in most ductal carcinoma in situ (DCIS; six out of
seven cases) which is noninvasive, and in noncancerous
components. However, AMAP1 protein expression was
high inall casesof DCISin patients simultaneouslybearing
IDC lesions (n = 9). Therefore, AMAP1 protein expression
appearsto be well correlated with the malignant potentials
of primary cancers of the human breast, rather than being
simply correlated with the invasive phenotypes (37).
Like Arf6, overexpression of the AMAP1 protein in highly
invasive breast cancer cells is also independent of the
transcriptional upregulation of the AMAP1 gene (37).
The 5’-UTR of AMAP1 mRNA also possesses a very
complicated secondary structure with a high free-energy
change ((40), Figure 2). We have observed that AMAP1
protein levels are downregulated in serum-starved MDA-
MB-231 cells, which is then upregulated swiftly upon EGF
stimulation;andmoreover,rapamycinreducestheAMAP1
protein levels in MDA-MB-231 cells (OBI, Osaka). The
5’-UTR of AMAP1 mRNA exhibits an internal ribosomal
entry site (IRES) activity in differentiated monocytes (40).
However, we have yet to study the precise mechanism
involved in enhanced translation of the AMAP1 mRNA in
malignant breast cancer cells (40).
Overexpression of AMAP1/DDEF1/ASAP1 in
Other Types of Tumors
Ampliﬁcation of chromosome 8q is frequently observed
in a broad range of solid tumors, including breast
cancer (41). The AMAP1/ASAP1/DDEF1 gene is located
at 8q24.12 (42,43). The DDEF1 protein has been shown
to also be overexpressed in high-grade primary uveal
melanomas, in which ampliﬁcation of chromosome
8q was found to correlate most strongly with the
expression of the DDEF1 mRNA (42). The ASAP1 protein
is also overexpressed in 80% of primary prostate
cancers, in which its expression is substantially higher
in metastatic lesions; and moreover, additional copies of
its gene are detected in 58% of primary prostate cancer
specimens (44). Like breast cancer cells, siRNA-mediated
knockdown of ASAP1 protein expression in prostate
cancer cells has been shown to effectively block their
migration and invasion (44). Thus, the genetic alterations
and mechanisms involved in AMAP1/ASAP1/DDEF1
overexpression differ among different types of cancers.
We have shown previously that AMAP1 also appears to
be involved in the invasion of glioblastomas and lung
cancers (45). It waits to be investigated as to how widely
AMAP1 is involved in the invasion and metastasis of
tumors with different organ and tissue origins.
GEP100 Activates Arf6 to Induce Invasion and
Metastasis
The human genome encodes 15 different proteins bearing
the Sec7 domain (the GEF domain for Arfs), which is three
times more than the number of Arf GTPases (7,15,46).
Among them, GEP100 (also called BRAG2) is responsible
for Arf6 activation which induces breast cancer cell
invasion and metastasis (47). GEP100 has been well-
documented biochemically to be a speciﬁc GEF for
Arf6 (48). On the other hand, other GEFs, including
ARNO and EFA6 which are also known to be robust
GEFs against Arf6, are not immediately involved in the
invasive activities, while these GEFs are also expressed
in breast cancer cells (47). Overexpression of GEP100
together with Arf6 made otherwise noninvasive MCF7
cells to be highly invasive, whereas co-overexpression
of ARNO and Arf6 did not (47). Therefore, distinct types
of GEFs activate Arf6 and evoke different functions of
Arf6 even within a single cell. Most ArfGEFs bear distinct
multifactorial protein- and lipid-interaction modules (13).
Different protein binding and/or membrane environments
of each GEF might determine their different involvement
in distinct cellular functions of Arf6. Such differences
among the Arf6GEFs might also be closely related
to the different ARF6 cargo speciﬁcities (also see
later).
Most ArfGAPs also have several multifactorial protein
interactionmodules (39),andtheabovenotionforArfGEFs
might also be true for ArfGAPs. On the other hand, one
should be very careful because forced overexpression of
different GEFs for Arf6 often evokes similar phenotypes
of plasma membrane blebbing and protrusion, which are
prototypes of Arf6 activation. The same is also true for
the overexpression of ArfGAPs, which might cause shut
down of the general activities of cellular Arf6.
EGFR Activates GEP100 through Direct
Interaction
Epidermal growth factor receptor (EGFR) is frequently
overexpressed in a large number of cancers, including
breast, lung, prostate, head and neck, and colon,
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Figure 3: The EGFR-GEP100-Arf6-AMAP1 pathway speciﬁc to cancer invasion and metastasis. Besides well-known EGFR signaling
pathways that link to the cell invasion and migration via activation of Ser/Thr kinases, EGFR can evoke a novel pathway that leads to the
cancer invasion and metastasis, in which phosphorylated Tyr1068 or Tyr1086 binds directly to the PH domain of GEP100. Through this
binding, GEP100 activates Arf6 and its downstream signaling pathway employing AMAP1 as its effector. For functioning of this pathway,
it is prerequisite that both Arf6 and AMAP1 are highly overexpressed, and that Tyr1068 or Tyr1086 is highly phosphorylated. This
EGFR-GEP100-Arf6-AMAP1 pathway plays pivotal roles not only in the formation and function of invadopodia, but also in perturbation of
the E-cadherin-based cell–cell adhesion. Arf6 can be ubiquitinated by Fbx8, a component of the SCF complex. Loss of Fbx8 expression
is frequently observed in different breast cancer cells, and contributes to their invasiveness. Monoubiquitination of AMAP1 by Cbl, via
AMAP1’s binding to CIN85, is also necessary for the invasion.
and is a biomarker of the poor prognosis of many
of these diseases (49,50). Moreover, EGF stimulation
has been shown to evoke invasive activities in some
breast cancer cells, including MDA-MB-231 (51). We
have shown that GEP100 directly binds to ligand-
activated EGFR to activate Arf6 (47). This binding is
mediated via an interaction of the pleckstrin homology
(PH) domain of GEP100 either with the Tyr1068- or
Tyr1086-phosphorylation sites of EGFR (47). The human
genome contains almost 100 different PH domains;
and only about 15% of them have been shown to
bind speciﬁcally to phosphoinositides, while most PH
domains may exhibit some detectable afﬁnities to
phosphoinositides (52). This is the ﬁrst demonstrationthat
a PH domain binds to phosphotyrosine. Consistently, both
Tyr1068 and Tyr1086 become heavily phosphorylated in
breast cancer cells upon EGF stimulation (47). On the
other hand, EGFR has nine major tyrosine phosphorylation
sites (53). Phosphorylation of Tyr1173 is very weak, and
phosphorylation of Tyr992, Tyr1045 and Tyr1148 is almost
undetectable in EGF-treated MDA-MB-231 cells (47).
Phosphorylation of Tyr845 has also been reported in
MDA-MB-231 cells (54). Phosphorylation of Tyr1068 and
Tyr1086 are both known to provide binding sites for
the src homology 2 (SH2) domains of Grb2, a binding
which may then lead to activation of the Ras-MAPK
pathway. However, the EGFR-GEP100 pathway does not
necessarily interfere with the EGF-dependent proliferation
of breast cancer cells (47); see Figure 3.
Mechanisms by Which the Arf6 Pathway
Functions in Tumor Invasion (I): Roles in
Invadopodia Formation and Phagocytosis
Tumor cells invade into basement membranes in
vitro through specialized structures, called invadopodia.
Bowden et al. have shown that cortactin and paxillin, both
known to be involved in actin-cytoskeletal remodeling, are
integral components of the invadopodia of MDA-MB-231
cells (22). We have shown that AMAP1 bridges cortactin
and paxillin, in which a proline-rich sequence of AMAP1
binds to the src homology 3 (SH3) domain of cortactin,
and the SH3 domain of AMAP1 binds to paxillin (37). This
trimeric protein complex is clearly detected only in highly
invasive breast cancer cells in which AMAP1 is abnormally
overexpressed, but not in noninvasive breast cancer
cells or normal mammary epithelial cells (37). Paxillin
and cortactin are relatively abundant proteins in most
cultured cells, including both invasive and noninvasive
breast cancer cells, and levels of the AMAP1 expression
seem to be crucial for formation of this trimeric protein
complex at detectable levels. Blocking of this trimeric
protein complex inhibits invadopodia formation as well as
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Figure 4: Hypothetical model as to how the EGFR-GEP100-Arf6-AMAP1 pathway functions in tumor invasion. Formation
and function of invadopodia consist of several steps, I–V, as depicted in this ﬁgure. I: Arf6 is activated by GEP100, bound to the
ligand-activated EGFR, and resides at or near the plasma membrane (PM). II: GTP-Arf6 then recruits its effector AMAP1, which is
associated with several different proteins including cortactin, paxillin, and perhaps also amphiphysin II (Amp II). AMAP1 is also indirectly
associated with certain types of integrins, and acts to recruit them to the plasma membrane. III: AMAP1, as well as its accessary
proteins, then remodel plasma membrane and cytoskeletal architecture to form membrane protrusions, which contain integrins. IV:
Inactivation of Arf6 is thought to precede the onset of the phagocytosis at invadopodia, although this is not yet completely proofed.
An ArfGAP responsible for the Arf6 inactivation in invadopodia is not identiﬁed. At around the same time, dynamin should be recruited
to invadopodia, a recruitment that is presumably mediated by amphyphisin or some equivalent molecules. For the recruitment of
dynamin by amphyphisin, amphyphisin needs to release the prebound AMAP1. V: Invadopodia are sites of the phagocytosis of degraded
extracellular matrices, which bind to integrins. The Bar domain of AMAP1 is thought to play a crucial role for invagination of the plasma
membrane. Dynamin is also an integral component for phagocytosis, which mediates the ﬁssion reaction of the endocytic vesicles from
the plasma membrane. A cue to start phagocytosis is not yet clariﬁed. Ubiquitination of AMAP1 by Cbl is not described in this ﬁgure,
for simpliﬁcation.
metastatic activities of breast cancer cells (37; also see
later). On the other hand, it should be noted that AMAP1
may have an alternative way of the complex formation
with cortactin. The SH3 domain of AMAP1 is known
to also bind to Fak (55). Bharti et al. have reported that
binding of the AMAP1 SH3 domain to Fak may mediate
a complex formation of AMAP1 with cortactin in NIH
3T3 cells (56). On the other hand, by expressing the
AMAP1 SH3 domain, we have shown that the AMAP1
SH3 domain is predominantly used for the binding to
paxillin, but not to cortactin, in malignant breast cancer
cells ((37); Figure 4).
Invadopodia are sites of the plasma membrane protrusion.
Fcγ receptor-mediated phagocytic cups of macrophages
are also formed as a consequence of the plasma
membrane protrusion; and it has been shown that
Arf6 is localized to Fcγ receptor-mediated phagosomes
and are necessary for their formation (16). The basic
function of GTP-Arf6 includes the ‘outward ﬂow’ of
membrane components and proteins into the plasma
membrane (10,57,58).Consistently,Arf6activatedby EGF
stimulation ofcells,aswellasArf6Q67L,recruitAMAP1to
the plasma membrane (36). It is thus plausible to assume
that GTP-Arf6 might act to recruit AMAP1 and its binding
partners, including cortactin and paxillin, to the plasma
membrane; and these proteins then start to remodel the
plasma membrane, as well as the cytoskeleton, to form
protrusive structures.
It has been shown in a mouse model of human breast
cancer that the β1 integrin subunit is pivotal for the tumor
progression, while its absence results in a state of tumor
cell dormancy (59). Moreover, α3β1 integrin is highly
implicated in invasion and metastasis of many primary
breast cancers, as well as MDA-MB-231 cells (60,61). Our
preliminary results indicate that AMAP1 also makes a
complex with β1 integrin to recruit it to sites of the Arf6
activation (OBI, Osaka).
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Invadopodia are also sites of matrix degradation and
phagocytosis of the degraded matrix fragments by use of
integrins.Fcγ receptor-mediatedphagocyticcupsbecome
invaginated during phagocytosis of opsonized particles.
We have shown that AMAP2 (also called Papα and PAG3),
a close isoform of AMAP1, is localized to Fcγ receptor-
mediated phagocytic cups as its integral component (62).
AMAP1 and AMAP2 both interact with several endocytic
proteins, including amphiphysin IIm and intersectin, to
recruit them to sites of the Arf6 activation (39,62).
Moreover, like amphiphysin II (63), AMAP1 and AMAP2
each has a Bar domain, which together with the PH
and ArfGAP domains, efﬁciently bend the surface of
large unilamellar vesicles (64). An electron microscopic
observation has indeed shown that AMAP2, as well
as Arf6, are localized at invaginated pits of the plasma
membrane (38).
AMAP1 is ubiquitinated, and this ubiquitination also
appears to be necessary for the involvement of AMAP1
in invasion (65). A mouse ortholog of AMAP1, ASAP1,
has been shown to bind to CIN85 (66), which is an
interacting protein of Cbl, an E3 ligase (67). AMAP1 was
then found to form a complex with Cbl through its binding
to CIN85 (65). Cbl mediates ubiquitination of AMAP1
mostly as monoubiquitination, and this ubiquitination
is not immediately linked to the rapid proteasomal
degradation (65). Cbl also mediates monoubiquitination
of ligand-activated EGFR at multiple sites (68,69), and
this ubiquitination has been shown to be closely
linked to recruitment of the ligand-activated EGFR to
endocytic pathways and their lysosomal degradation to
downregulate the EGFR signaling (70,71). Given that
AMAP1 forms a complex with integrins, it is possible
that monoubiquitination of AMAP1 is necessary for its
lysosomal recruitment, in order to degrade the matrix
fragments phagocytosed by AMAP1-bound integrins. On
the contrary, however, interaction of AMAP1 with CIN85
has been implicated in recycle-back of EGFR to the
plasma membrane (72). Understanding the role of AMAP1
monoubiquitination, as well as its interaction with CIN85,
is an aspect important to clarify the precise roles of
AMAP1 in invasion.
Dynamin is a large GTPase that mediates ﬁssion reaction
of vesicles from the donor membrane, and is hence
important for the ﬁnal onset of the phagocytosis (73).
Dynamin interacts with endocytic proteins including
amphiphysin IIm, and locates at the neck of budding
vesicles (73). Our results implicated that change of
the binding partner of amphiphysin IIm from AMAP2
to dynamin-2 is necessary for the ﬁnal onset of
endocytosis (36,38). On the other hand, there is an
implication that hydrolysis of GTP bound to Arf6 is also
necessary for endocytosis of certain receptors, such as
transferrin receptors (74). It waits to be clariﬁed whether
hydrolysis of GTP bound to Arf6, as well as what
kind of other cues (ex, cues for the changing of the
partner of amphiphysin IIm from AMAP1/2 to dynamin-2)
are necessary for the ﬁnal onset of phagocytosis from
invadopodia.
M e c h a n i s mb yw h i c ht h eA r f 6P a t h w a y
Functions in Tumor Invasion (II): Roles in the
Disruption of E-cadherin-based Cell–Cell
Adhesion
In addition to the formation of invadopodia, disruption
of E-cadherin-based cell–cell adhesion is a hallmark of
the acquisition of invasive and metastatic phenotypes of
most tumors with epithelial origins (75–77). Arf6activityis
thought to be pivotal for the assembly and disassembly of
E-cadherin-based cell–cell adhesions: it has been shown
that an activeform of Arf6, Arf6Q67L, causes disassembly
of E-cadherin-mediated adherens junctions in MDCK cells,
while its inactive form, Arf6T27N, blocks the hepatocyte
growth factor (HGF)-induced internalization of E-cadherin-
based junctional components (17,18). Experiments using
fetal hepatocyte cells prepared from Arf6–/– mice
also support this notion (78). We have shown that the
expression and activation of Arf6 by GEP100 in MCF7
cellsbycDNAtransfectionperturbstheirE-cadherin-based
cell–cell adhesion (47). Consistently, GEP100 has been
previously implicated in endocytosis of E-cadherin (79)
and recycling of β1 integrin (80), although the precise
mechanisms are unknown. We have shown, on the other
hand, that the activation of Arf6 by other GEFs, such as
ARNO,doesnotblockE-cadherin-basedcell–celladhesion
in MCF7 cells (47).
Cadherins and integrins do not possess conventional
endocytic signals. Endocytosis of such plasma membrane
proteins devoid of conventional endocytic signals (hence
thought to be endocytosed independent of clathrin)
has actually been implicated to occur along a pathway
regulated by Arf6 (81–83). In the case of MHC-I, which
also lacks a conventional endocytic signal, Arf6 has been
shown to regulate the formation of EHD1-containing
tubules, which then regulate MHC-I recycling (84). On the
other hand, recent reports have shown that E-cadherin
can be endocytosed through the clathrin-dependent
pathway (17,18,85); and that GTP-Arf6 is also involved
in the recruitment of the clathrin/AP-2 complex to
membranes (86,87). Molecular mechanisms as to how
Arf6 is involved in endocytosis of E-cadherin are totally
unknown.
The EGFR-GEP100-Arf6-AMAP1 Pathway in
Primary Tumors of the Human Breast
About 20–40% of breast tumors have been reported
to be positive for EGFR (88). We observed that about
40% of ductal carcinoma in situ (DCIS) specimens are
positive for EGFR, while EGFR positivity per se does not
correlate with their grades or comedo forms (the most
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aggressive form) (47). On the other hand, about 60% of
DCIS specimens were positive for GEP100, while GEP100
positivity per se did not correlate with tumor grades (47).
However, we found that double-positivity for EGFR and
GEP100 expression correlated with tumor grades (47).
Moreover, more than 80% of EGFR-positive DCIS of
grades 2 and 3 were positive for GEP100 (47). In the
case of IDC, about 40% were also positive for EGFR
and more than 80% were positive for GEP100 (47). The
difference in GEP100 positivity between IDC and DCIS
specimens was also found to be statistically signiﬁcant.
Again, more than 90% of EGFR-positive IDC specimens
were positive for GEP100 (47). These observations are
supportive of the notion that EGFR predominantly utilizes
GEP100 for the development of malignancy in mammary
ductal carcinomas. These observations, together with
the aforementioned observations of Arf6 and AMAP1
expression, also suggest that the EGFR-GEP100-Arf6-
AMAP1 pathway is frequently used in a substantially
large population of primary ductal carcinomas for the
development of malignancy.
Among the four members of the EGFR family, ErbB2 (also
called Neu and Her2) is also overexpressed in 20–30%
of breast tumors, while the coexpression analysis did not
ﬁnd a signiﬁcant positive or negative correlation between
EGFR and ErbB2 overexpression (89–91). About 90% of
the comedo forms of DCIS are positive for ErbB2, and
DCIS stratiﬁed according to Scott’s system showed that
ErbB2 is related to a subgroup with worse prognosis (90).
Fifteen to thirty percent of IDCs also show c-erbB2
gene ampliﬁcations and its overexpression (90). We have
shown that co-overexpression of GEP100 and Arf6 in
MCF7 breast cancer cells induces invasiveness, which
is substantially dependent on EGF stimulation (47). On
the other hand, overexpression of ErbB2 is sufﬁcient to
induce the migration and invasion of MCF7 cells, even
in the absence of ligands (92). Induction of the malignant
phenotypes by ErbB2, however, appears to be mediated
at least partly through its pleiotropic functions, including
transcriptional inactivation of the E-cadherin gene (93),
direct interaction with the E-cadherin protein to perturb
E-cadherin function (94), and association with the laminin
receptor α6β4 integrin (95). We have previously shown
that ErbB2, expressed at a basal level in MDA-MB-231
cells, is not coprecipitated with GEP100 (47). However,
these results do not deny the possibility that ErbB2 can
associate with GEP100, when ErbB2 is overexpressed
at very high levels by its gene ampliﬁcation and hence
heavily tyrosine phosphorylated (see below). Moreover,
EGFR can heterodimerize with ErbB2 to produce a more
robust signal than EGFR–EGFR homodimers (89,93).
ErbB2 contains a tyrosine residue which may correspond
to Tyr1068 and Tyr1086 of EGFR (50). Therefore, it will be
worth investigating whether GEP100 also has the ability
to interact with ErbB2, that is highly overexpressed and
heavily tyrosine phosphorylated. If this is the case, cancer
cells, bearing overexpressed ErbB2 and the GEP100-Arf6-
AMAP1 pathway, may not require exogenous factors for
their invasion and metastasis. It will also be interesting
to examine whether the EGFR/EGFR homodimer or the
EGFR/ErbB2heterodimer,whenactivatedbyligandsother
than EGF (89), employ GEP100. Moreover, it also waits
to be determined whether other members of the EGFR
family, besides EGFR and ErbB2, also employ GEP100.
Hepatocyte growth factor receptor (HGFR; also called c-
Met) tyrosine kinase is also expressed in 20–40% of
breast tumors and is highly implicated in cell motility and
malignancy (96,97). HGFR also contains tyrosine residues
which are heavily phosphorylated upon activation. If
GEP100 also interacts with HGFR besides EGFR, about
40–80% of breast cancers may utilize the GEP100-Arf6-
AMAP1 pathway, although this might not be the sole
pathway for their invasion and malignancy.
Fight Against Breast Cancer by Use of
Knowledge Regarding the Arf6 Pathway
in Invasion
TheEGFR-GEP100-Arf6-AMAP1pathwayprovidesseveral
novel molecular targets for breast cancer therapeutics. As
already discussed (98–100), this pathway might provide
alternative targets for the treatment of patients with
cancer that has become resistant to the currently
available EGFR inhibitors. Moreover, overexpression and
ampliﬁcation of EGFR in breast cancers correlates
inversely with their estrogen receptor status (101–103).
Therefore, this pathway may also provide alternative
targets for patients with cancer resistant to endocrine
treatments.
siRNA-mediated knockdown of GEP100, Arf6 and AMAP1
each effectively inhibits the invasive activities of breast
cancer cells (20,37,47). However, Arf6 is expressed
ubiquitously in different types of cells, organs and
tissues, and may have housekeeping roles. AMAP1
and GEP100 are also expressed widely. Therefore,
general knockdown of their expression might cause
some unexpected side effects to human health. On
the other hand, only highly invasive breast cancer cells
exhibit detectable levels of the complex formation of
AMAP1 with cortactin (37). This binding interface appears
to provide an excellent molecular target (45). In this
complex, AMAP1 binds to the SH3 domain of cortactin
via its proline-rich sequence, SKKRPPPPPPGHKRT (P4
peptide, (37)).Therearealmost250differentSH3domains
encoded in the human genome (104), and SH3 domains
bind to their cognate proline-rich ligands generally with
a one-to-one stoichiometry (105). On the other hand,
the AMAP1 and cortactin binding is very atypical in its
stoichiometry, in which one AMAP1 P4 peptide binds
to two cortactin SH3 domains simultaneously (45). In
accordance with this, ﬁne structural analysis has revealed
a very unusual way of binding of SH3-Pro in the AMAP1-
cortactin complex (45). Therefore, it should be possible to
design speciﬁc blockers of this SH3-Pro binding that do
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not effectively inhibit other canonical SH3/Pro bindings.
Indeed, we have demonstrated that a cell permeable
form of the P4 peptide, as well as the small compound
UCS15A, effectively block AMAP1/cortactin binding and
block breast cancer invasion and metastasis, while these
blockers do not efﬁciently inhibit other canonical SH3/Pro
bindings (45).
The binding interface between EGFR and GEP100 also
appears to be unusual, given that PH domains generally
exhibit afﬁnities to phosphoinositides (52). Moreover, a
small molecule inhibitor that speciﬁcally interacts with
the Sec7 domain of cytohesins has been reported (106).
Generation of small molecule inhibitors that speciﬁcally
block the EGFR and GEP100 binding, or interact with
the GEP100 Sec7 domain will be useful for cancer
therapeutics.
Future Perspectives
Extensive efforts are being carried out to develop gene
expression proﬁling-based diagnostic tests for breast
tumors, including those for prognostic tests and predictive
tests for endocrine- and chemotherapy-sensitivity. It
should be kept in mind, however, that recent studies
using comparative genomic and proteomic proﬁling have
documented a lack of correlation between the mRNA
and protein levels of numerous genes (107,108). mRNAs
under posttranscriptional control encode proteins involved
in cell adhesion, signal transduction, growth control, and
transcriptional control, hence posttranscriptionalcontrol of
protein production provides rapid and speciﬁc responses,
such as to stress, apoptosis, and proliferative and
oncogenic stimuli. Accordingly, our study revealed that
abnormally high levels of expression of Arf6 and AMAP1
proteins in malignant breast cancer cells are primarily
because of the posttranscriptional regulation of their
mRNAs or proteins. Further development of ‘protein
expression proﬁling’ technology will deﬁnitely contribute
to the more ﬁne stratiﬁcation of patients.
Our results show that the EGFR-GEP100-Arf6-AMAP1
pathway requires EGF for activation. It has been highly
implicated that tumor-associated macrophages, rather
than carcinoma cells, are the major source of EGF
in mammary tumors (109,110). Consistently, over 80%
of cases of human breast cancers bearing high densi-
ties of macrophage accumulation in their microenviron-
ments have a poor prognosis (111). The crucial roles of
macrophages in the development of the invasive and
metastatic phenotypes of mammary tumors have also
been documented in a mouse model experiment (112).
However, there are alternative lines of evidence support-
ing that immune cells accumulating in the microenviron-
ments and inﬁltrating into the tumor mass may have a
role in eliminating cancer cells, as exempliﬁed in ovar-
ian caricinomas and melanomas (113,114). Tumors are
tissue-speciﬁc diseases, and their invasive and metastatic
phenotypes are highly diverse, as mentioned in the begin-
ning of this review. We have discussed in this review
that the majority of human ductal cancers may utilize
the GEP100-Arf6-AMAP1 pathway for their malignancy
that is activated by growth factor receptor signaling.
Identiﬁcation of the ﬁne signaling pathways and mech-
anisms that are frequently used in each type of cancer
for their invasion and metastasis will greatly contribute
to the further understanding of the distinct outcomes of
cancer-microenvironment interactions. Such information
should then greatly contribute to the further development
of cancer therapeutics, including immune therapy.
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